ABSTRACT This paper explores the ethical implications of emerging weight‐loss medications such as Semaglutide (Ozempic) and Tirzepatide (Mounjaro), analysing their therapeutic applications for obesity and potential use as enhancement drugs. These medications promise significant benefits, including improved individual health outcomes, reduced healthcare costs and, potentially, reduced environmental harms. However, their widespread adoption raises various concerns, such as unknown long‐term side effects, the exacerbation of weight‐based discrimination, and the reinforcement of socioeconomic disparities. The paper argues that, with robust regulatory frameworks in place, the potential benefits of these medications are likely to outweigh the risks. Nonetheless, ongoing monitoring of their effect on individuals and society at large remains essential.
Francesca Minerva (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: